NYSE:DPLO (USA) Also trade in: Germany

Diplomat Pharmacy Inc

$ 6.03 0.14 (2.38%)
Volume: 155,246 Avg Vol (1m): 803,231
Market Cap $: 449.78 Mil Enterprise Value $: 1.08 Bil
P/E (TTM): 0.00 P/B: 0.96
Earnings Power Value -4.37
Net Current Asset Value -6.33
Tangible Book -5.49
Projected FCF 9.75
Median P/S Value 23.97
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5.2/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Equity-to-Asset 0.32
Equity-to-Asset range over the past 10 years
Min: -0.12, Med: 0.45, Max: 0.59
Current: 0.32
-0.12
0.59
Debt-to-Equity 1.38
Debt-to-Equity range over the past 10 years
Min: -16.48, Med: 0.25, Max: 3.34
Current: 1.38
-16.48
3.34
Debt-to-EBITDA -3.44
Debt-to-EBITDA range over the past 10 years
Min: -4.37, Med: 1.52, Max: 27.57
Current: -3.44
-4.37
27.57
Interest Coverage 0.68
Interest Coverage range over the past 10 years
Min: 0.68, Med: 5.27, Max: 15.18
Current: 0.68
0.68
15.18
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.15
DISTRESS
GREY
SAFE
Beneish M-Score -2.69
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 2.22%
WACC 9.08%

Profitability & Growth : 6/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 0.52
Operating Margin range over the past 10 years
Min: 0.41, Med: 0.73, Max: 1.36
Current: 0.52
0.41
1.36
Net Margin % -5.85
Net Margin range over the past 10 years
Min: -5.85, Med: 0.29, Max: 0.77
Current: -5.85
-5.85
0.77
ROE % -49.40
ROE range over the past 10 years
Min: -49.77, Med: 5.02, Max: 7.62
Current: -49.4
-49.77
7.62
ROA % -18.88
ROA range over the past 10 years
Min: -18.88, Med: 1.02, Max: 3.7
Current: -18.88
-18.88
3.7
ROC (Joel Greenblatt) % -183.12
ROC (Joel Greenblatt) range over the past 10 years
Min: -183.12, Med: 11.88, Max: 56.75
Current: -183.12
-183.12
56.75
3-Year Total Revenue Growth Rate 17.70
3-Year Revenue Growth Rate range over the past 10 years
Min: 4.3, Med: 30.8, Max: 55.8
Current: 11.5
4.3
55.8

» DPLO's 30-Y Financials

Financials (Next Earnings Date: 2019-08-06)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:DPLO

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers    NAICS : 325412    SIC : 2834
Compare NAS:FLXN TSXV:FLWR NAS:OPTN ASX:EXL TSX:FIRE XKRX:249420 CAI:PHAR.CA XCNQ:FONE XCNQ:CWEB SZSE:300584 XKRX:086450 BSP:OFSA3 TSE:4577 XKRX:229500 TSXV:LABS SZSE:000790 SHSE:603079 SZSE:002864 HKSE:02633 HKSE:01652
Traded in other countries 7DP.Germany
Address 4100 South Saginaw Street, Flint, MI, USA, 48507
Diplomat Pharmacy Inc is active within United States' healthcare sector. It offers a range of services related to medical care, especially pharmacy solutions for chronic diseases such as hepatitis, multiple sclerosis, and other long-term conditions. Furthermore, it renders clinical services, drug-specific compliance, and persistency programs support, patient financial assistance and clinical and administrative support services to hospitals. The company derives most of its revenue through prescription drug sales in the United States.

Ratios

Current vs industry vs history
PB Ratio 0.96
PB Ratio range over the past 10 years
Min: 0.7, Med: 2.27, Max: 9.4
Current: 0.96
0.7
9.4
PS Ratio 0.09
PS Ratio range over the past 10 years
Min: 0.06, Med: 0.33, Max: 1.06
Current: 0.09
0.06
1.06
Price-to-Operating-Cash-Flow 42.93
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 9.01, Med: 19.9, Max: 85.96
Current: 42.93
9.01
85.96
EV-to-EBIT -3.87
EV-to-EBIT range over the past 10 years
Min: -6.7, Med: 64.9, Max: 227.5
Current: -3.87
-6.7
227.5
EV-to-EBITDA -5.91
EV-to-EBITDA range over the past 10 years
Min: -10.5, Med: 20.7, Max: 109
Current: -5.91
-10.5
109
EV-to-Revenue 0.21
EV-to-Revenue range over the past 10 years
Min: 0.2, Med: 0.5, Max: 1.3
Current: 0.21
0.2
1.3
Current Ratio 1.00
Current Ratio range over the past 10 years
Min: 0.82, Med: 1.13, Max: 2.09
Current: 1
0.82
2.09
Quick Ratio 0.66
Quick Ratio range over the past 10 years
Min: 0.56, Med: 0.73, Max: 1.58
Current: 0.66
0.56
1.58
Days Inventory 13.32
Days Inventory range over the past 10 years
Min: 7.11, Med: 14.88, Max: 18.29
Current: 13.32
7.11
18.29
Days Sales Outstanding 21.09
Days Sales Outstanding range over the past 10 years
Min: 19.9, Med: 25.59, Max: 28.49
Current: 21.09
19.9
28.49
Days Payable 20.55
Days Payable range over the past 10 years
Min: 20.55, Med: 34.88, Max: 36.43
Current: 20.55
20.55
36.43

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -4.80
3-Year Share Buyback Rate range over the past 10 years
Min: -12.8, Med: -7.2, Max: -0.4
Current: -4.8
-12.8
-0.4

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.62
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.59, Med: 1.55, Max: 2.1
Current: 0.62
0.59
2.1
Price-to-Median-PS-Value 0.25
Price-to-Median-PS-Value range over the past 10 years
Min: 0.24, Med: 1.03, Max: 2.85
Current: 0.25
0.24
2.85
Earnings Yield (Joel Greenblatt) % -25.81
Earnings Yield (Greenblatt) range over the past 10 years
Min: -29.3, Med: 1.2, Max: 4.8
Current: -25.81
-29.3
4.8

More Statistics

Revenue (TTM) (Mil) $ 5,406.85
EPS (TTM) $ -4.24
Beta 1.24
Volatility % 71.51
52-Week Range $ 4.17 - 26.37
Shares Outstanding (Mil) 74.71

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N